奎硫平与奋乃静治疗老年男性精神分裂症对照研究

A control study of quetiapine vs perphenazine in the treatment of senile male schizophrenia

目的探讨奎硫平与奋乃静治疗老年男性精神分裂症的临床疗效和安全性。方法将51例老年男性精神分裂症患者随机分为两组，研究组26例，口服奎硫平治疗，对照组25例，口服奋乃静治疗，观察12w。于治疗前及治疗第6w、12w末采用阳性与阴性症状量表及副反应量表评定临床疗效和不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著性下降（P〈0．01），并随着治疗时间的延续呈持续性下降；治疗12w末，研究组总分及阴性症状因子分显著低于对照组（t=2．4、2．4，P〈0．05）；研究组显效率为76．92％，有效率为92．31％；对照组分别为72．0％、88．0%，两组无显著性差异（u=0．50，P〉0．05）。研究组不良反应发生率及各时点副反应量表评分均显著低于对照组（P均〈0．05）。结论奎硫平治疗老年精神分裂症疗效与奋乃静相当，但改善阴性症状显著优于奋乃静，且安全性高，依从性好。

Objective To explore the clinical efficacy and safety of quetiapine vs perphenazine in the treatment of senile male schizophrenia. Methods Fifty-one senile male schizophrenics were randomly assigned to research group （n=26） took orally quetiapine and control group （n=25） did perphenazine for 12 weeks. Before treatment and at the end of the 6th and 12th week, clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS）. Results After treatment, the total and each factor scores of the PANSS of both groups lowered more significantly compared with pretreatment（P〈0.01） and did continously with treatment; at the end of the 12th week, the total and negative scores were significantly lower in the research than in the control group（P〈0.05） ; obvious effective and effective rates were respectively 76.92% and 92.31% in the research and 72. 0% and 88.0% in the control group, which showed no significant differences（P〉0.05）. Incidneces of adverse reactions and each timepoint TESS score were significantly lower in the research than in the control group（all P〈0.05）. Conclusion Quetiapine has an evident effect equivalent to perphenazine in the treatment of senile shcizophrenia, is more effective on negative symptoms than the latter, and has higher safety and better compliance.